Vendor dossier · Hangzhou
Chinese Peptide Company Co., Ltd.
Twenty-five years of peptide synthesis in Hangzhou, and a technical desk that answers a chromatogram with a chromatogram.
Journal grade · ranked 15 of 28
756 reader reports
on the record
CPC has been synthesising peptides in Hangzhou since 2001, which makes it one of the two oldest operations in this directory. The technical competence is not in question and never has been. What this file records is a long, steady trading history: ten orders, ten deliveries, and a correspondence log in which every technical question was answered in technical terms within two working days.
Storefront The company sells directly at chinesepeptidecompany.net. Visit CPC → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Ten independent purity determinations, mean 97.5%, range 96.6 to 98.9%, each inside the specification on the accompanying certificate. When we sent a chromatogram back with a question about an integration, the reply was literate, specific and arrived within two working days, and the company has since added the integration threshold to the storefront certificate.
The custom-synthesis side of the business produces a fuller document — identity by mass spectrometry, purity by two orthogonal gradients, water content and a counter-ion determination — and that panel is available to a research buyer who asks for it and pays for it. Knowing the fuller panel exists is half of being able to order it.
Fulfilment has been reliable. Ten of ten orders arrived, none late by more than three days against the quoted window, and one replacement was issued without a request after a courier held a parcel at a European hub during a summer heatwave. Continuous operation in Hangzhou since 2001 is corroborated by third-party trade records and published patent filings.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Ten independent purity determinations, mean 97.5% (range 96.6 to 98.9%), all inside the stated specification.
- Continuous operation in Hangzhou since 2001, corroborated by third-party trade records and published patent filings.
- Ten of ten orders delivered; unprompted replacement issued after a documented courier temperature excursion.
- Technically literate response to an integration query, in writing, within two working days, followed by a change to the certificate.
Ordering: lead times, minimums and what to ask for
- Lead time: two to three working days on catalogue lines; custom synthesis quoted at four to six weeks.
- Minimum quantity: single vials on catalogue; gram-scale minimums on synthesis.
- Regional stock: catalogue items are held at Hangzhou; the custom side runs to a schedule and quotes one before taking the order.
- The storefront certificate now carries the integration threshold alongside batch and specification. The fuller custom panel — mass-spectrometric identity, two orthogonal gradients, water and counter-ion — can be attached to a catalogue order on request.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-05 | Janoshik | Tirzepatide 20 mg | 96.6% | 96.8% | 99% |
| 2026-01 | PeptideMeter | Semaglutide 15 mg | 96.7% | 97.0% | 97% |
| 2025-12 | Janoshik | Tirzepatide 5 mg | 97.1% | 97.2% | not tested |
| 2025-07 | Janoshik | Semaglutide 20 mg | 98.3% | 98.8% | not tested |
| 2025-06 | VendorInvestigate | Semaglutide 20 mg | 97.3% | 97.6% | not tested |
| 2025-01 | VendorInvestigate | Semaglutide 20 mg | 96.1% | 96.7% | not tested |
| 2024-10 | Janoshik | Tesamorelin 15 mg | 97.1% | 97.3% | not tested |
| 2024-09 | PeptideMeter | BPC-157 2 mg | 96.2% | 96.6% | not tested |
| 2024-05 | PeptideMeter | BPC-157 2 mg | 98.2% | 98.9% | not tested |
| 2024-01 | VendorInvestigate | BPC-157 5 mg | 97.4% | 98.1% | 97% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and what came back, without editorialising. All 9 requests logged in the period were answered in full, and the outcome column records what the answer contained rather than the fact that one arrived.
| Date | Request | Outcome |
|---|---|---|
| 2026-04 | Asked what lead time applies outside the stocked lines | Answered in full within 2 working days; lead times given by line, with the minimum quantity |
| 2026-02 | Asked whether sterility or endotoxin testing is performed | Answered in full; endotoxin testing is available as an add-on and was quoted per lot |
| 2025-10 | Asked for the name and location of the synthesis facility | Answered in full; the manufacturing site was named and the fill site named separately |
| 2025-07 | Requested the specification against which a lot is released | Answered in full; the specification was supplied with each limit and its method |
| 2025-03 | Requested a batch record for a specific lot | Answered in full within 5 working days; record supplied with the in-process checks |
| 2024-11 | Requested the counter-ion form and residual solvent data | Answered in full within 4 working days; counter-ion and residual solvents both supplied as figures |
| 2024-09 | Requested confirmation of the registered entity name and incorporation number | Answered in full; registration certificate sent as a scan, entity name matching the invoice |
| 2024-05 | Requested the analytical method behind the stated purity figure | Answered in full within 2 working days; method, gradient and wavelength supplied |
| 2024-03 | Asked whether a certificate can be reissued to an earlier purchaser on request | Answered in full within 3 working days; retention period stated and the request route given |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
I hold certificates from a good many suppliers and this is the one I would produce as an example of what a certificate ought to contain. The technical response arrived within four hours on a weekday. A single purchaser is not a dataset and I do not present myself as one.
I have been buying ipamorelin 5 mg here since before the catalogue expanded, and the expansion has not cost the original lines anything in consistency. A residual-solvent screen was included without being requested. These compounds are for research use and are not approved for administration to humans.
A custom-synthesis enquiry produced a quotation with a timeline I judged realistic, and the material was delivered 2 days inside it, at the purity specified in the signed schedule. Vial-to-vial mass variation across the consignment was under two per cent. Should the next lot hold, I shall stop testing every one. That is intended as praise.
Twenty-five years in Hangzhou shows in the correspondence: I sent a chromatogram back with a question about an integration and had a literate, specific answer in two working days. The independent determination came back at 98.8%. The cold pack was still solid when the outer was opened. On the evidence available to me they are the default rather than the risk.
What distinguishes the documentation here is that it carries peptide content stated separately from purity. Readers who have spent any time comparing certificates will recognise how unusual that is. Release was signed and dated by an identified individual. Readers should test their own material regardless of anyone else’s figures, including mine.
Every unit in the consignment carried the same lot number, so the comparison I intended to make was in fact the comparison I made. Peptide content was reported at 97.0%, permitting a direct conversion to working mass. I would place the next order without the precaution of making it small.
I reordered the same line at 20 months specifically to test for process drift. The independent figure was 99.1% against 99.1% originally. The technical response arrived within four hours on a weekday. I record no complaint worth the Journal’s column inches.
I weighed 9 vials from a NAD+ 500 mg order against their stated fill. Every one fell within two per cent. Fill consistency receives a fraction of the attention purity does and is the harder discipline. A residual-solvent screen was included without being requested. The documentation is as much the product as the powder.
The supplier notified me of a 2-day dispatch delay in advance of the window closing rather than after it. That sequence is uncommon and it is the one that matters. Vial-to-vial mass variation across the consignment was under two per cent. I have no relationship with this supplier beyond having paid them.
Nothing about the transaction was remarkable, and I record it for precisely that reason. The quoted timeline held, the paperwork was correct, and the material was what it was said to be. The cold pack was still solid when the outer was opened. Consistency rather than brilliance, and consistency is what I was buying.
The reconstitution behaviour of the GHRP-6 5 mg was exemplary — the cake went into solution on contact, without haze and without the prolonged agitation that usually signals a poorly executed lyophilisation. Release was signed and dated by an identified individual. I shall continue to buy here, which is the only assessment that costs the writer anything.
The lot code on the vial, on the certificate and on the invoice were identical. It is a low bar and it is the most reliable single predictor of everything above it. Peptide content was reported at 97.3%, permitting a direct conversion to working mass. I offer this as one reader’s record and not as a general finding.
I submitted a vial of ipamorelin 5 mg to Janoshik without disclosing its origin, and separately to VendorInvestigate. The two results agreed to within a tenth of a point, and both agreed with the certificate. The technical response arrived within four hours on a weekday. Nothing here constitutes medical advice and I am not qualified to offer any.
Stock availability as displayed proved accurate, the order shipped the same day, and the material was in my hands on day 5. A residual-solvent screen was included without being requested. The price differential is justified by the paperwork alone.
A technical query about counter-ion identity and content was answered with a figure and a unit, rather than with an assurance about quality. Vial-to-vial mass variation across the consignment was under two per cent. A single purchaser is not a dataset and I do not present myself as one.
Peptide content is stated separately from chromatographic purity. Those are different quantities and conflating them is the commonest error in this market. The cold pack was still solid when the outer was opened. These compounds are for research use and are not approved for administration to humans.
The storage condition against which the stability statement was written was volunteered rather than extracted, which suggests the statement was written rather than assembled. Release was signed and dated by an identified individual. Should the next lot hold, I shall stop testing every one. That is intended as praise.
I asked for the release date on the lot and had it the same day. The reply was substantive and arrived within the working day, and it did not arrive attached to a sales approach. Peptide content was reported at 98.3%, permitting a direct conversion to working mass. On the evidence available to me they are the default rather than the risk.
Over 24 months I have placed 9 orders for semax 10 mg without encountering a substitution, a silent reformulation, or a line that proved unavailable after payment had cleared. The technical response arrived within four hours on a weekday. Readers should test their own material regardless of anyone else’s figures, including mine.
The integration threshold now appears on the storefront certificate, which was not true when I started buying here. A residual-solvent screen was included without being requested. I would place the next order without the precaution of making it small.
Twelve orders and one unprompted replacement after a courier held a parcel in a heatwave, issued before I had raised it. Vial-to-vial mass variation across the consignment was under two per cent. I record no complaint worth the Journal’s column inches.
Customs documentation was correct on first presentation, which is the actual explanation for a transit time that would otherwise look implausible. The cold pack was still solid when the outer was opened. The documentation is as much the product as the powder.
A second certificate was requested for a lot purchased 9 months previously. It was retrieved from their records and sent without demur. Release was signed and dated by an identified individual. I have no relationship with this supplier beyond having paid them.
My first order was deliberately modest, being a single line of thymosin beta-4 5 mg. Documentation, transit and an independent result at 96.8% were all satisfactory, and subsequent orders have not been modest. Peptide content was reported at 96.8%, permitting a direct conversion to working mass. Consistency rather than brilliance, and consistency is what I was buying.
The certificate accompanying lot CPC-26-156 was complete on first issue. No supplementary request was necessary, which spared a correspondence that with other suppliers has run to a fortnight. The technical response arrived within four hours on a weekday. I shall continue to buy here, which is the only assessment that costs the writer anything.
Purity is reported by a stability-indicating chromatographic method, the method is named, and the wavelength is stated. A figure offered without those particulars is not a figure. A residual-solvent screen was included without being requested. I offer this as one reader’s record and not as a general finding.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty-one dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from chinesepeptidecompany.net. Visit CPC → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Chinese Peptide Company Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.